The Pediatric Trials Network’s Post

FDA Approves Crinecerfont for Adult, Pediatric Patients with Congenital Adrenal Hyperplasia: The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points. #finance #pharmacy #lifesciences

Remestemcel-L-rknd Receives FDA Approval for SR-aGvHD in Pediatric Patients: The approval makes remestemcel-L-rknd the first approved mesenchymal stromal cell in the United States. #finance #pharmacy #lifesciences

TestBank for Abrams Clinical Drug Therapy;Rationale for Nursing Practice 13E by Frandsen;Pennington https://lnkd.in/dv4R975P #ClinicalDrugTherapy #RationalesForNursingPractice #PharmacologyConcepts #MedicationAdministration #DrugTherapyLifespan #HematopoieticSystem #ImmuneSystem #InflammationInfection #CardiovascularSystem #RespiratorySystem #RenalSystem #EndocrineSystem #CentralNervousSystem #EyeEarSkinDisorders.

To successfully execute a pediatric clinical trial, drug developers must adopt a patient-centric approach that minimizes participant burden, while ensuring compliance with regulatory requirements and ethical considerations for this special population. 📥 Download this white paper for insights into the nuances of pediatric trials. » https://bit.ly/3Tf0lAN

ℹ️ Pediatric Drug Development faces unique challenges, from ethical considerations to dosing complexities and the need for age-appropriate formulations. Understanding and addressing these challenges is crucial for creating #effective treatments for our youngest patients. Wondering how pediatric patients are classified? Our #infographic provides a #comprehensive breakdown, covering everything you need to know about this vital aspect of drug development. #PediatricDrugDevelopment #HealthcareInnovation #Paediatrics #MedicalResearch #SymmetricTraining

FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis: The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS). #finance #pharmacy #lifesciences

To successfully execute a pediatric clinical trial, drug developers must adopt a patient-centric approach that minimizes participant burden — while ensuring compliance with regulatory requirements and ethical considerations for this special population. 📥 Download this insightful paper to explore the nuances of successful pediatric drug development. #clinicaltrials #drugdevelopment #patientrecruitment

June is Alzheimer’s and Brain Awareness Month. Let's raise awareness and support those affected by Alzheimer’s. Together, we can make a difference. #alzheimersawareness #brainhealth #endalz #caregivers #fightalzheimers #brainawareness #bonitapharma #stressfree #nocontracts #stressfreesolutions #hasslefree #pharmacysolutions #pharmaceuticalcare #bonitapharmaceuticals #pharmaceuticals #medicalsupplies #topmeds #healthcaresolutions #pharmacydeals #otcoptions #healthcareaccess #pharmacydiscounts #westlandmi #pharmainventory #bonita #pharmacy #healthcareforyou #drugstore #medicine #distributor #medications

$CVKD~ About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Is Developing Tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions. Tecarfarin has an orphan drug designation for the prevention of thrombosis and thromboembolism in patients with ventricular assist devices (VADs). Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation. Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with thrombotic antiphospholipid syndrome. Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in 11 human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com. https://lnkd.in/g8XCZvRm

Historically, many drugs have been prescribed to children even though this patient population have largely been excluded from clinical trials. Our latest blog explores key elements of pediatric development plans (PSP/PIP) and the challenges of global harmonization. Read more: https://hubs.ly/Q02CsT1N0 #PediatricResearch #ClinicalTrials #Pharma #Healthcare #DrugDevelopment